Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott R Plotkin

Showing results (111-120 of 201) with videos related to

Pageof 21
Sort By:
Neurology|July 7, 2021
Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement: Lessons From REiNSVanessa L Merker, Andrés J Lessing, Irene Moss, et al.
European Journal of Human Genetics : EJHG|April 27, 2021
Identifying challenges in neurofibromatosis: a modified Delphi procedureBritt A E Dhaenens, Rosalie E Ferner, Annette Bakker, et al.
The New England Journal of Medicine|June 21, 2024
Brigatinib in <i>NF2</i>-Related Schwannomatosis with Progressive TumorsScott R Plotkin, Kaleb H Yohay, Phioanh L Nghiemphu, et al.
Journal of Neuro-Oncology|September 8, 2010
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomideElizabeth R Gerstner, April F Eichler, Scott R Plotkin, et al.
Neurology|August 17, 2016
Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1Scott R Plotkin, Stephanie D Davis, Kent A Robertson, et al.
Clinical Biochemistry|December 25, 2012
Plasma S100β is not a useful biomarker for tumor burden in neurofibromatosisMiriam J Smith, Sonia Esparza, Vanessa L Merker, et al.
Current Oncology (Toronto, Ont.)|March 28, 2023
Proton Radiotherapy for Vestibular Schwannomas in Patients with NF2-Related Schwannomatosis: A Case SeriesJules P J Douwes, Kimberley S Koetsier, Victor S van Dam, et al.
Familial Cancer|December 16, 2025
"It's not any one thing, it's always all of them, all at the same time": quality of life in NF2-related schwannomatosis from patient and clinician perspectivesSophia C Carias, Frank D Buono, Liesel Von Imhof, et al.
The Laryngoscope|June 13, 2025
Increased Hemorrhage During Excision of Bevacizumab-Treated NF2-Related Vestibular SchwannomasChristopher G Wood, Liana Kozanno, Anat Stemmer-Rachamimov, et al.
Annals of Clinical and Translational Neurology|May 30, 2021
Transcriptomic signature of painful human neurofibromatosis type 2 schwannomasPhanidhar Kukutla, Sherif G Ahmed, Daniel M DuBreuil, et al.
Pageof 21

Showing results (111-120 of 201) with videos related to

Sort By:
Pageof 21
Neurology|July 7, 2021
Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement: Lessons From REiNSVanessa L Merker, Andrés J Lessing, Irene Moss, et al.
European Journal of Human Genetics : EJHG|April 27, 2021
Identifying challenges in neurofibromatosis: a modified Delphi procedureBritt A E Dhaenens, Rosalie E Ferner, Annette Bakker, et al.
The New England Journal of Medicine|June 21, 2024
Brigatinib in <i>NF2</i>-Related Schwannomatosis with Progressive TumorsScott R Plotkin, Kaleb H Yohay, Phioanh L Nghiemphu, et al.
Journal of Neuro-Oncology|September 8, 2010
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomideElizabeth R Gerstner, April F Eichler, Scott R Plotkin, et al.
Neurology|August 17, 2016
Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1Scott R Plotkin, Stephanie D Davis, Kent A Robertson, et al.
Clinical Biochemistry|December 25, 2012
Plasma S100β is not a useful biomarker for tumor burden in neurofibromatosisMiriam J Smith, Sonia Esparza, Vanessa L Merker, et al.
Current Oncology (Toronto, Ont.)|March 28, 2023
Proton Radiotherapy for Vestibular Schwannomas in Patients with NF2-Related Schwannomatosis: A Case SeriesJules P J Douwes, Kimberley S Koetsier, Victor S van Dam, et al.
Familial Cancer|December 16, 2025
"It's not any one thing, it's always all of them, all at the same time": quality of life in NF2-related schwannomatosis from patient and clinician perspectivesSophia C Carias, Frank D Buono, Liesel Von Imhof, et al.
The Laryngoscope|June 13, 2025
Increased Hemorrhage During Excision of Bevacizumab-Treated NF2-Related Vestibular SchwannomasChristopher G Wood, Liana Kozanno, Anat Stemmer-Rachamimov, et al.
Annals of Clinical and Translational Neurology|May 30, 2021
Transcriptomic signature of painful human neurofibromatosis type 2 schwannomasPhanidhar Kukutla, Sherif G Ahmed, Daniel M DuBreuil, et al.
Pageof 21